Additionally, a low incidence of concurrent PD-L1 expression and CD8+ TILs in EGFR-mutant NSCLC tumors has been observed [85,89], possibly explaining the lower immune response in NSCLC patients with EGFR mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.